December 3, 2020 C-Path Selects Aridhia to Support Rare Disease Cures Accelerator-Data and Analytics Platform TUCSON, Ariz., December 3, 2020 — The Critical Path Institute (C-Path) today announced it has selected Aridhia to support
C-Path, Ltd. Announces New Contract with Innovative Medicines Initiative DUBLIN, Ireland, December 3, 2020 — Critical Path Institute, Ltd. (C-Path, Ltd.) announced today a new contract with the
C-Path Quantitative Medicine Program Awarded FDA Contract to Develop Tools for Neuroscience Diseases TUCSON, Ariz., December 2, 2020 — The Critical Path Institute (C-Path) today announced it has been awarded a U.S. Food an
Alzheimer’s Disease Data Initiative Launches, Critical Path for Alzheimer’s Disease Consortium to Partner CPAD will partner with ADDI to build better tools for researchers around the world to access, use and share dementia-relate
Pediatric IBD Foundation, ImproveCareNow, C-Path to Establish the Children’s Registry for the Advancement of Therapeutics TUCSON, Ariz., November 5, 2020 — The Pediatric IBD Foundation, ImproveCareNow, and the Critical Path Institute (C-Path)
FDA Awards C-Path Grant to Use Real-World Data to Generate Real-World Evidence in Neonates Pilot project will include the development of a Real-World Data and Analytics Platform TUCSON, Ariz., October 27, 2020 — Arizona
Rare Disease Cures Accelerator-Data and Analytics Platform First Year Milestones Highlighted at Virtual Workshop C-Path, NORD, FDA and more come together to showcase the importance of data sharing in rare disease drug development
C-Path Launches Consortium to Accelerate Medical Product Development in Sickle Cell Disease September is National Sickle Cell Awareness Month TUCSON, Ariz., Sept. 17, 2020 — The Critical Path Institute (C-Path) today
C-Path’s PSTC, D-RSC Receive Positive FDA Response for Drug-Induced Skeletal Muscle Injury Biomarkers Safety biomarkers aim to provide an additional tool for detecting acute drug-induced skeletal muscle injury in phase 1 clinical tr
C-Path’s PSTC, D-RSC Receive Positive FDA Response to Plan for Liver Safety Biomarker Biomarker aims to provide an additional tool for detecting the onset of hepatic injury in clinical trials involving patients with
